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mpact  of  human  immunodeﬁciency  virus
nfection on the  clinical  presentation  and  outcome
f community-acquired  pneumonia  in hospitalized
 caigerian adults:  a  multicenter
ear Editor,
ommunity-acquired pneumonia (CAP) is an important cause
f  morbidity and mortality both in human immunodeﬁ-
iency virus (HIV)-infected inividuals,1 and in the general
opulation.2 So far, the effect of HIV infection on the out-
ome  of CAP is controversial. While there is evidence that
IV-infected persons with CAP have increased mortality com-
ared  with HIV negative individuals,1 similar outcomes in
oth  groups have also been reported.3 However, the role of
o-morbidities was  not completely established in a good num-
er  of the observations.1,3 In addition, some of the studies
ncluded a substantial proportion of HIV-infected patients
eceiving ART,1 which further complicates the scenario. There
s  limited information about the effect of HIV infection on
he  evolution of CAP in sub-Saharan Africa. We  investigated
he  impact of HIV on CAP by comparing the clinical presen-
ation  and in-hospital outcomes of CAP between ART-naive
IV-infected and HIV negative Nigerian patients who had no
o-morbidities.
We conducted a ﬁve-year multicenter retrospective
ase–control study of patients hospitalized with CAP between
anuary  1, 2008 and December 31, 2012 in four major refer-
al  hospitals in South East Nigeria. Standard CAP deﬁnition
as  used.4 Patients with co-morbidities or opportunistic
espiratory infections were  excluded. After applying the
xclusion  criteria, we enrolled a consecutive sample of 44
IV-infected patients with CAP (cases) and 234 HIV negative
atients  with CAP (control). Demographic, clinical, laboratory
nd  treatment data were  obtained from the patients’ fold-
rs.  The primary outcome was  in-hospital mortality while
he  secondary outcome was  length-of-hospital stay (LOS).se–control  study
Patients  whose sputum culture yielded organisms other
than  Streptococcus pneumoniae were categorized as having
CAP  of non-pneumococcal etiology. Pneumonia severity was
assessed  using the CURB-65 scoring system.5
Data analyses were performed using the Epi Info
version 3.5.3. Comparisons between cases and controls
were carried out using the chi-square or Fisher’s exact
test  for qualitative variables, and Student’s t-test or
non-parametric equivalents for quantitative variables as
appropriate.  p-Value <0.05 was  considered statistically signif-
icant.
The  results are shown in Table 1. HIV-infected patients
were signiﬁcantly younger than the controls (37 vs. 49
years,  p = 0.0002), otherwise both groups had similar socio-
demographic characteristics and received comparable treat-
ments.  While the control group had a higher proportion of
patients  with sputum production (73 vs. 54%, p = 0.01) and
chest  pain (28 vs. 14%, p = 0.04); fever (89 vs. 73%, p = 0.02)
and  breathlessness (75 vs. 58%, p = 0.04) were  more frequent
in  the cases. HIV-infected patients were more likely to have
severe  pneumonia as assessed by the CURB-65 score (38.7
vs.  6.0%, p < 0.0001), and were also more  likely to have ane-
mia  (p < 0.0001) and hyperglycemia (p = 0.002). HIV-infected
patients had higher in-hospital mortality (54.5 vs. 8.5%,
p  < 0.0001) and longer LOS among survivors (13 vs.10 days,
p  = 0.03).
In conclusion, we  found that HIV infection negatively
impacts on CAP clinical presentation, overall mortality, and
LOS  among survivors. Corroborating our ﬁndings in large
prospective cohort studies would have strong implications for
the management of CAP in HIV-infected populations espe-
cially  in sub-Saharan Africa.
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Table 1 – Characteristics of HIV-infected and HIV negative patients with community-acquired pneumonia.
HIV+ve with CAP (N = 44) HIV−ve with CAP (N = 234) p-Value
Characteristics
Female gender 24 (54.5) 121 (51.7) 0.73
Age (yrs), mean ± SD 36.8 ± 11.9 48.6 ± 18.8 0.0002
Age > 65 years 3 (6.8) 58 (24.8) 0.008
Social class 0.60
1–2  (upper) 14 (31.8) 84 (35.9)
3–5  (lower) 30 (68.2) 150 (64.1)
Urban residence 22 (50.0) 141 (60.3) 0.21
Ever smoked 8 (18.2) 21 (9.0) 0.07
Alcohol use 13 (29.5) 49 (20.9) 0.21
Time to ﬁrst in-hospital assessment (hrs), median (IQR) 1.0 (0.5–2.5) 1.3 (1.0–3.0) 0.09
Time to ﬁrst in-hospital antibiotics (hrs), median (IQR) 6.0 (2.5–10.0) 4.0 (3.0–7.0) 0.11
Antibiotics basis 0.63
Entirely empirical 26 (59.1) 129 (55.1)
Changed to sensitivity pattern 18 (40.9) 105 (44.9)
Class of antibiotics received 0.96
Penicillin  18 (40.9) 101 (43.2)
Cephalosporin 10 (22.7) 55 (23.4)
Fluoroquinolone 12 (27.3) 62 (26.5)
Macrolide 2 (4.5) 16 (6.8)
Received oxygen 14 (31.8) 104 (44.4) 0.12
ICU admission 0 (0.0) 2  (0.9) 0.54
Symptom duration (days), median (IQR) 8  (3.5–14) 5  (3–7) 0.0003
Clinical features
Cough  37 (84.1) 200 (85.5) 0.81
Sputum production 24 (54.5) 171 (73.1) 0.01
Breathlessness 33 (75.0) 137 (58.5) 0.04
Chest pain 6 (13.6) 66 (28.2) 0.04
Fever 39 (88.6) 170 (72.6) 0.02
RR (breaths/min) 36.7 ± 9.5 32.9 ± 9.9 0.003
SBP (mmHg) 108.6 ± 21.2 116.1 ± 18.8 0.003
DBP (mmHg) 68.9 ± 15.0 73.4 ± 12.6 0.04
CURB-65 score <0.0001
0–2  32 (61.3) 220 (94.0)
≥3  12 (38.7) 14 (6.0)
Laboratory parameters
Chest  X-ray ﬁnding 0.37
Unilobar consolidation 37 (84.1) 208 (88.9)
Multilobar consolidation 7 (15.9) 26 (11.1)
Sputum isolatea, n (%) 0.09
Pneumococcal 7 (31.8) 71 (52.2)
Non-pneumococcal 9 (40.9) 36 (26.5)
No  pathogen 6 (27.3) 19 (15.1)
Serum urea (mmol/l) 8.3 ± 3.5 5.0 ± 2.1 <0.0001
Blood glucose (mmol/l) 8.6 ± 3.1 6.9 ± 1.9 <0.0001
Hemoglobin (g/dl) 8.4 ± 2.9 11.3 ± 1.7 <0.0001
WBC (mm3), median (IQR) 6400  (4800–11,550) 9300 (5800–13,100) 0.03
Outcome variables
Length-of-hospital stay (days)
Survivors  12.6 ± 6.1 10.3 ± 4.4 0.03
Dead 6.4 ± 5.9 6.3 ± 2.8 0.96
Survivors and dead 9.9 ± 4.7 9.2 ± 5.5 0.32
Mortality 24 (54.5) 20 (8.5) <0.0001
Except where stated, values are n (%) or mean ± standard deviation; HIV, human immunodeﬁciency virus; CAP, community-acquired pneumonia;
ICU, intensive care unit; SD, standard deviation; IQR, interquartile range; DBP, diastolic blood pressure; SBP, systolic blood pressure; WBC, white
blood cell count.
a 22 HIV-infected and 126 HIV negative patients had sputum cultures available of which only 16 and 107 patients, respectively, had organisms
isolated. The non-pneumococcal organisms included the following: HIV-infected (Klebsiella pneumoniae = 7, Staphylococcus aureus = 2) and HIV
negative (K. pneumoniae = 19, S. aureus = 8, Streptococcus pyogenes = 9).
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